Actinium’s HuM195 mAb is being tested for treatment of myeloid leukemia.
PacificGMP will manufacture and perform fill/finish of Actinium Pharmaceuticals’ HuM195 monoclonal antibody for a Phase I/II clinical trial. A stability study of the final product will also be conducted. HuM195 is a monoclonal antibody that is currently being tested in a Phase I clinical trial to treat acute myeloid leukemia.
